ent-dextilidine and Chronic-Pain

ent-dextilidine has been researched along with Chronic-Pain* in 2 studies

Reviews

1 review(s) available for ent-dextilidine and Chronic-Pain

ArticleYear
[Chronic non-cancer-related pain. Long-term treatment with rapid-release and short-acting opioids in the context of misuse and dependency].
    Schmerz (Berlin, Germany), 2013, Volume: 27, Issue:1

    Annually published data show a continual increase in the volume of opioid prescriptions in Germany, thus indicating an intensification of opioid therapy. The majority of opioids are prescribed to treat chronic non-cancer-related pain. On the basis of current guidelines, as well as in terms of the lack of data regarding long-term use of opioids and their effectiveness beyond a period of 3 months, this development must be viewed critically. With reference to four case reports, we discuss and evaluate opioid therapy in relation to medication misuse and the development of drug dependency. Particular emphasis is placed on the administration of rapid-release and short-acting opioid preparations, which we consider to be particularly problematic.

    Topics: Abdominal Pain; Adult; Analgesics, Opioid; Chronic Pain; Diabetic Neuropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Utilization; Female; Fentanyl; Guideline Adherence; Headache Disorders; Humans; Long-Term Care; Male; Middle Aged; Opioid-Related Disorders; Oxycodone; Physician-Patient Relations; Practice Patterns, Physicians'; Prescription Drug Misuse; Risk Factors; Tilidine

2013

Other Studies

1 other study(ies) available for ent-dextilidine and Chronic-Pain

ArticleYear
[Management of chronic pain using extended release tilidine : Quality of life and implication of comedication on tilidine metabolism].
    Schmerz (Berlin, Germany), 2017, Volume: 31, Issue:5

    The synthetic opioid tilidine is often used in chronic pain treatment. However, the activation via metabolism in patients with concomitant medication and reduced liver or kidney function is not thoroughly investigated. We therefore studied pain treatment efficacy, health-related quality of live and the metabolism of tilidine in patients with chronic pain.. In all, 48 patients, who were on a stable dose of oral prolonged release tilidine for at least 7 days, were included in this observational multicenter study. Liver and kidney function were assessed in routine blood samples, concentrations of tilidine, nortilidine and bisnortilidine were determined using a validated LC/MS/MS method. Comedication was registered and patients experience with regard to quality of life, pain, gastrointestinal symptoms and adverse events was assessed in standardised questionnaires.. On average a daily dose of 180 mg tilidine was taken. Dose normalized plasma concentrations of the active metabolite nortilidine ranged between 1.6 ng/ml and 76.5 ng/ml (mean 29.2 ± 25.1 ng/ml). Ratios between tilidine and nortilidine were on average 0.28 (median = 0.13, standard deviation = 0.67). Patients were on 1 to 14 different concomitant medications. About 66% of the patients had sufficient pain treatment. Almost no opioid-induced constipation was observed. Only few patients had decreased kidney or liver function which did not result in elevated nortilidine concentrations.. Pain treatment using tilidine resulted in variable nortilidine concentrations which are obviously not strongly influenced by comedication or reduced liver or kidney function. Only a few side effects were observed with almost no opioid-induced constipation.

    Topics: Adult; Aged; Aged, 80 and over; Chronic Pain; Delayed-Action Preparations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Quality of Life; Tilidine

2017
chemdatabank.com